Skip to content

    Best Agrolife

    BESTAGRO
    Chemicals·9 Feb 2026
    Management Summary

    Best Agrolife reported a challenging Q3 FY26 with significant revenue decline due to unseasonal rainfall and market conditions. Despite this, the company showed operational improvements with a positive EBITDA and reduced OPEX. The patented product portfolio demonstrated resilience, and new product launches received strong farmer acceptance. Management expressed confidence in returning to growth in the coming quarters, driven by their patented products and cost optimization efforts.

    Highlights

    5

    • Q3 FY26 EBITDA improved to ₹3.8 crores from a loss of ₹5.8 crores in Q3 FY25

    • Q3 FY26 EBITDA margin improved to 1.9% from negative 2.1% in Q3 FY25

    • OPEX (excluding financial depreciation) reduced by 36% in Q3 and 20% over 9M FY26

    • Patented product portfolio showed resilience with only a 5% reduction in 9M FY26

    • New patent products BestMan and Fetagen have treated over 4 lakh acres each and received strong farmer acceptance

    Concerns

    5

    • Q3 FY26 Revenue from operations declined by 25.9% YoY to ₹202.9 crores from ₹274.1 crores

    • 9M FY26 Revenue from operations declined by 28.5% YoY to ₹1,101 crores from ₹1,540 crores

    • 9M FY26 sales declined by 28%, with 23% due to volume decline and 5% due to price variation

    • Company reported a loss of ₹12.7 crores in Q3 FY26

    • Unseasonal high rainfall in October 2025 significantly impacted Q3 sales and cropping cycle

    What Changed2

    vs Q4 FY26

    Guidance items8 → 7 (-1)Risks discussed6 → 5 (-1)
    Key financials

    Metrics

    8

    Periods

    2

    Q3 FY26

    4
    • Revenue
      ₹202.9 Cr
      YoY-25.9%
    • EBITDA
      ₹3.8 Cr
    • EBITDA Margin
      1.9%
    • PAT
      ₹-12.7 Cr

    9M FY26

    4
    • Revenue
      ₹1,101 Cr
      YoY-28.5%
    • EBITDA
      ₹127 Cr
    • EBITDA Margin
      11.5%
    • PAT
      ₹46.1 Cr

    Capital allocation

    2
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    FY26 Revenue
    ₹1,300 crores to ₹1,400 crores
    		High
    Revenue
    FY27 Revenue
    ₹1,600 crores, ₹1,700 crores, ₹1,800 crores
    		High
    Revenue
    Next year (FY27) Revenue
    higher than ₹1,500 crore, ₹1,600 crore and then going up to ₹1,700 crore, ₹1,800 crore
    		High
    EBITDA Margin
    FY26 EBITDA Margin
    around 12%
    		High
    EBITDA Margin
    FY27 EBITDA Margin
    16% to 17% minimum
    		High
    Profitability
    Q4 FY26 Profitability
    not to have losses
    		High
    Capacity Utilization
    Revenue potential from existing capacity
    ₹2,000-plus crore
    		High

    Q4 FY26 Profitability

    next quarter
    CurrentLoss of ₹12.7 crores in Q3 FY26
    TargetNo losses, small profit

    Why it matters

    To confirm management's commitment to avoid losses in Q4 and demonstrate improved financial discipline.

    Our expectation is not to have losses, so in Q4 last year we had very high losses, so based on already we have worked on the OPEX part which we are reducing drastically. So, sales, obviously, as I said, the demand is a little softer, so we do not expect very high sales, but we expect not to go into losses and have even a small profit, but our plan is not to have losses.

    How to verify

    key_financials.metrics[label='PAT (Q4 FY26)']

    Risks & concerns

    5
    RiskSeverity

    Unseasonal rainfall and adverse weather conditions

    October 2025 witnessed exceptionally high rainfall (49% higher than long-period average), disrupting sowing, produce, and overall cropping cycle, leading to lower sales. — Management acknowledged

    high

    High inventory at trade level and price competition

    Industry faced challenges related to high generic inventory at the trade level, leading to higher price competition and affecting demand. — Management acknowledged

    medium

    Potential El Nino effect in next financial year

    Management acknowledged reports of El Nino effects, stating they will work with caution on the supply chain and inventory, but existing policies will help manage impact. — Analyst acknowledged

    medium

    Warrant issue payment uncertainty

    The exercise price of warrants is significantly higher than the current market price, creating uncertainty about the payment of the remaining 75% of the issue. — Analyst acknowledged

    medium

    Delayed receivables

    Receivables over six months have increased due to delayed payments from government/farmers, though management states they are under control and expects improvement by March. — Analyst acknowledged

    medium

    Q&A highlights

    7

    “So, Hemant, mostly in the sales, if you are aware, most part of September, August and September and including October, there was continuous rainfall. Especially in the north, most of the flooding has also happened. So, this impacted a little bit of sales. So we were pretty confident that we will be positive.”

    Analyst challenged management's prior confident guidance for H2 FY26, leading to an explanation of weather impacts and focus on cost control to limit losses.

    asked by Hemant Gupta

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY26 Performance Overview and Challenges

    Best Agrolife reported a challenging Q3 FY26 with revenue from operations declining by 25.9% YoY to ₹202.9 crores. The company posted a loss of ₹12.7 crores for the quarter. For the nine months ended December 31, 2025, revenue stood at ₹1,101 crores, a 28.5% decrease YoY. This decline was primarily attributed to unseasonal rainfall and market-related factors, including high inventory at the trade level and increased price competition.

    02

    Operational Efficiency and Cost Optimization

    Despite the revenue decline, Best Agrolife demonstrated improved operational efficiency. The company achieved a positive EBITDA of ₹3.8 crores in Q3 FY26, a significant improvement from a loss of ₹5.8 crores in Q3 FY25, with the EBITDA margin rising to 1.9%. OPEX, excluding financial depreciation, was reduced by 36% in Q3 and 20% over the nine-month period, contributing to better financial discipline.

    03

    Patented Product Portfolio and Innovation

    The company's patented product portfolio showed resilience, with only a 5% reduction in sales for the nine-month period, compared to a 48% decline in the non-patent portfolio. Newly launched patent combinations, BestMan and Fetagen, have been well-received by farmers, treating over 4 lakh acres each. Best Agrolife secured three patents for novel combination formulations and a process patent for an intermediate, and filed four international patent applications, strengthening its global IP position.

    04

    International Business and Export Focus

    Best Agrolife is actively expanding its international footprint, with registration for patented products progressing in Sri Lanka and dossier preparation underway for Vietnam and Morocco. The company finalized its third export shipment to Sudan on a cash basis. They are also exploring opportunities in nano-urea and identifying intermediates for sale abroad, aiming for higher-margin export revenues.

    05

    Financial Outlook and Future Growth Targets

    Management expects to close FY26 with revenue between ₹1,300-1,400 crores and an EBITDA margin of around 12%. For FY27, they project revenue to grow to ₹1,600-1,800 crores with an EBITDA margin of 16-17% minimum. The company believes the worst is behind them and anticipates growth to return from next year, driven by new products and a stabilized operational structure. Existing capacity can support over ₹2,000 crores in revenue.

    06

    Capital Allocation and Warrant Issue Status

    The company has put CAPEX on hold, stating they are not doing anything as of now, and existing capacity is sufficient for the next two years. Proceeds from the preferential issue (25%) were utilized for working capital. The remaining 75% of the warrant issue is pending, and management is awaiting market conditions to decide on its payment, acknowledging the significant difference between the exercise price and current market price.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.